ArticleFrontiers in public health2026
Time-adjusted direct medical costs of moderate-to-severe chronic graft-versus-host disease: a retrospective two-center cost analysis in Türkiye.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic graft-versus-host disease (cGVHD) imposes a substantial economic burden after allogeneic hematopoietic cell transplantation, yet evidence on cost determinants is limited, particularly from middle-income countries. The determinants of the daily intensity of direct medical costs in moderate-to-severe cGVHD were examined. Methods: Fifty patients treated between 2018 and 2023 at two private transplant centers in Türkiye were analysed retrospectively. Because treatment durations varied, cost was modeled as an intensity per day of observation using a Gamma generalized linear model with a log link and a log-time offset and robust (HC1) standard errors. Cost components and mortality were examined as exploratory analyses. Results: The mean total direct cost was 52,979 USD (SD 47,697), comprising medication (75.7%), inpatient (23.1%), and outpatient (1.3%) costs. Daily cost intensity was higher in male patients (cost ratio 2.163, 95% CI 1.451-3.224; +116% per day) and lower with older age (cost ratio 0.970 per year; -3.0% per year). Disease severity, transplant type, and organ involvement showed no association with daily cost intensity (joint Wald Discussion: Daily cost intensity was determined chiefly by male sex and younger age, whereas severity acted on cumulative cost through longer treatment. These hypothesis-generating findings support time-adjusted cost analysis in cGVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.